Menu
Recruiting NCT07286929

Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma

Observational Glioma Parietal Lobe Glioma Visuspatial Deficit Unilateral Spatial Neglect (USN)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Glioma, Parietal Lobe Glioma, Visuspatial Deficit, Unilateral Spatial Neglect (USN). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of modern neurooncological surgery is to obtain maximum tumor resection while preserving neurological function. Parietal lobe gliomas often cause attention deficits (hemineglect) that are difficult to differentiate from other deficits. This study aims to evaluate the extent and variation over time of visuo-spatial deficits in patients undergoing surgical removal of parietal lobe gliomas. This will help characterize the cognitive profile of these patients to identify personalized treatment and rehabilitation paths.

Detailed description

This is a single-centre, prospective, cross-sectional, observational study involving 40 patients with high- and low-grade parietal lobe glioma. The study investigates the prevalence of subjects who show a performance in cognitive visuo-spatial tests below the cut-off of the normative sample. It evaluates associations with patient-reported outcome measures (ADL, IADL), clinical-demographic aspects, radiological data (MRI), and histological/molecular data. Assessments occur at screening (pre-surgery), and at follow-up visits (3-4 months and 6 months post-surgery). Neuropsychological tests include Line Bisection, Bell and Letter Cancellation, Reading test, Apple Cancellation, and Fluff test.

Primary outcome measures

  • Change in Visuospatial Deficit Prevalence [Time frame: Baseline (pre-surgery), 3-4 months post-surgery, 6 months post-surgery.]
Secondary outcome measures (4)
  • Association with Radiological Data [Time frame: Up to 6 months post-surgery]
  • Association with Clinical-Demographic Data [Time frame: Up to 6 months post-surgery.]
  • Association with Performance Status [Time frame: Time Frame: Up to 6 months post-surgery.]
  • Association with Histological/Molecular Data [Time frame: Up to 6 months post-surgery.]

Eligibility criteria

Inclusion criteria

  • Patients >18 years old
  • Patients must understand the Italian Language
  • Patients with suspected parietal lobe glioma

Exclusion criteria

  • Tumor site other than parietal lobe.
  • Patients who cannot undergo surgical resection (stereotactic/open biopsy).
  • Patients who received a previous chemotherapy and/or radiotherapy treatment.
  • Patients with a history of intracranial mass lesion or traumatic brain injury.
  • Patients with a history of other CNS diseases (e.g., stroke, metastasis).
  • Patients with diagnosis of neurodegenerative disease (i.e. Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease, Lewy Body Dementia, Amyotrophic Lateral Sclerosis).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Italy · 1 center
  • Fondazione IRCCS Istituto Neurologico Carlo Besta — Milan

Identifiers

NCT: NCT07286929 · neGLIO

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗